Skip to the main content.

1 min read

FORMULATIONS SPOTLIGHT: Elsie Melsopp

Name: Elsie Melsopp, Ph.D.Elsie_Melsopp_ScientistSpotlightjpg.jpg

Alcami Site: Wilmington, NC

How long have you been with Alcami?

I joined the company on March 17, 2017.

What is your role?

I lead the solids formulation development group, which is part of development services at our OSD manufacturinte site in Wilmington, NC.

What is the most rewarding part of your job?

Sharing the success of our customers and contributing to the pharmaceutical sciences.

What are your team’s latest achievements? 

  1. A formulation platform for controlled release 
  2. Mini-tablet technology suitable for a wide variety of applications such as: multi-particulates for IR and CR delivery, orally disintegrating tablets, pediatrics or geriatric oral dosage forms.

How do you see those accomplishments affecting the pharmaceutical industry?

Alcami offers product lifecycle options to the pharma industry. We innovate, continually developing new tools and programs to assist with the development of a new or existing (old) drug substance. By extending the release of a drug product or diversifying the oral administration, side effects are reduced and efficacy can be improved.

1 min read

Case Study: OSD Formulation Development

Client Profile The client needed formulation development of an oral dosage form from scratch. They required one month of stability data on a lead...

Read More

2 min read

Case Study: Challenges and Solutions to Formulating an Orphan Drug

According to the Food and Drug Administration and the Orphan Drug Designation program, orphan status is applicable to drugs and biologics which are...

Read More

1 min read

QbD Addresses API Supply in Orphan Drug Formulation

According to the Food and Drug Administration and the Orphan Drug Designation program, orphan status applies to drugs and biologics defined as “those...

Read More